Rocket One Inc. Common Stock (NASDAQ:RKTO) Trading at $0.32

Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report)’s share price was up 0% during mid-day trading on Monday. The stock traded as high as $0.3362 and last traded at $0.3210. 160,732 shares traded hands during trading, a decline of 52% from the average session volume of 332,302 shares. The stock had previously closed at $0.3209.

Analyst Ratings Changes

RKTO has been the subject of a number of research reports. Weiss Ratings upgraded Rocket One Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 29th. Wall Street Zen upgraded shares of Rocket One Inc. Common Stock from a “strong sell” rating to a “sell” rating in a report on Sunday, October 25th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.00.

Check Out Our Latest Report on Rocket One Inc. Common Stock

Rocket One Inc. Common Stock Trading Up 0.0%

The stock has a market cap of $7.99 million, a P/E ratio of -0.51 and a beta of 1.01. The stock’s 50-day moving average is $0.59 and its 200-day moving average is $0.82.

Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.11) EPS for the quarter.

Institutional Investors Weigh In On Rocket One Inc. Common Stock

A hedge fund recently raised its stake in Rocket One Inc. Common Stock stock. Lido Advisors LLC raised its position in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO – Free Report) by 100.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 39,000 shares of the company’s stock after purchasing an additional 19,500 shares during the quarter. Lido Advisors LLC owned about 0.20% of Rocket One Inc. Common Stock worth $33,000 as of its most recent SEC filing. Institutional investors and hedge funds own 7.08% of the company’s stock.

Rocket One Inc. Common Stock Company Profile

(Get Free Report)

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.

Further Reading

Receive News & Ratings for Rocket One Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket One Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.